Travere Therapeutics Inc
TVTX15.535USD
-0.095-0.61%
交易中 （美東）報價延遲15分鐘
1.38B總市值
虧損本益比TTM
關於 Travere Therapeutics Inc 公司
Travere Therapeutics, Inc. 是一家生物製藥公司。該公司專注於爲患有罕見腎臟和代謝疾病的患者識別、開發和提供改變生活的療法。其產品 FILSPARI (sparsentan) 適用於降低患有原發性 IgAN 且有快速疾病進展風險的成人患者的蛋白尿。Sparsentan 還處於局竈節段性腎小球硬化症 (FSGS) 的後期開發階段。該公司的 Pegtibatinase 是一種新型的試驗性人類酶替代候選藥物，正在評估用於治療經典同型胱氨酸尿症 (HCU)，這是一種罕見的代謝性疾病。其商業產品 Thiola 和 Thiola EC 用於治療胱氨酸尿症，這是一種罕見的遺傳性胱氨酸轉運障礙，會導致尿液中胱氨酸水平高和複發性腎結石的形成。該公司還致力於識別 Alagille 綜合徵 (ALGS) 的潛在小分子療法。
公司簡介
公司代碼TVTX
公司名稱Travere Therapeutics Inc
上市日期Jul 23, 2003
CEODr. Eric M. Dube, Ph.D.
員工數量385
證券類型Ordinary Share
年結日Jul 23
公司地址3611 Valley Centre Dr
城市SAN DIEGO
上市交易所NASDAQ Global Market Consolidated
國家United States of America
郵編92130
電話18889697879
網址https://travere.com/
公司代碼TVTX
上市日期Jul 23, 2003
CEODr. Eric M. Dube, Ph.D.
公司高階主管
名稱
名稱/職務
職務
持股
持股變動
Dr. Eric M. Dube, Ph.D.
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
129.71K
--
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Independent Director
Independent Director
81.00K
+8.72%
Mr. Peter Heerma
Mr. Peter Heerma
Chief Commercial Officer
Chief Commercial Officer
75.38K
+4.36%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
51.00K
+14.61%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Director
Independent Director
49.00K
+15.29%
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Chief Research Officer
47.41K
+3.77%
Ms. Elizabeth E. Reed
Ms. Elizabeth E. Reed
Chief Legal Officer, General Counsel and Corporate Secretary
Chief Legal Officer, General Counsel and Corporate Secretary
39.89K
--
Dr. Roy D. Baynes, M.D., Ph.D.
Dr. Roy D. Baynes, M.D., Ph.D.
Independent Director
Independent Director
31.00K
+26.53%
Mr. John A. Orwin
Mr. John A. Orwin
Independent Director
Independent Director
28.88K
+29.05%
Mr. Ron R. Squarer
Mr. Ron R. Squarer
Independent Director
Independent Director
28.88K
+29.05%
查看更多
名稱
名稱/職務
職務
持股
持股變動
Dr. Eric M. Dube, Ph.D.
Dr. Eric M. Dube, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
129.71K
--
Mr. Jeffrey A. Meckler
Mr. Jeffrey A. Meckler
Independent Director
Independent Director
81.00K
+8.72%
Mr. Peter Heerma
Mr. Peter Heerma
Chief Commercial Officer
Chief Commercial Officer
75.38K
+4.36%
Mr. Gary A. Lyons
Mr. Gary A. Lyons
Independent Chairman of the Board
Independent Chairman of the Board
51.00K
+14.61%
Mr. Timothy P. (Tim) Coughlin, CPA
Mr. Timothy P. (Tim) Coughlin, CPA
Independent Director
Independent Director
49.00K
+15.29%
Dr. William E Rote, Ph.D.
Dr. William E Rote, Ph.D.
Chief Research Officer
Chief Research Officer
47.41K
+3.77%
收入明細
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
FILSPARI
55.88M
0.00%
Tiopronin Products
19.98M
0.00%
暫無數據
業務
地區
業務USD
名稱
營收
佔比
FILSPARI
55.88M
0.00%
Tiopronin Products
19.98M
0.00%
股東統計
更新時間: 5月17日 週六
更新時間: 5月17日 週六
持股股東
股東類型
持股股東
持股股東
佔比
Armistice Capital LLC
9.99%
Janus Henderson Investors
8.48%
BlackRock Institutional Trust Company, N.A.
7.56%
The Vanguard Group, Inc.
6.75%
Macquarie Investment Management
5.40%
Other
61.82%
持股股東
持股股東
佔比
Armistice Capital LLC
9.99%
Janus Henderson Investors
8.48%
BlackRock Institutional Trust Company, N.A.
7.56%
The Vanguard Group, Inc.
6.75%
Macquarie Investment Management
5.40%
Other
61.82%
股東類型
持股股東
佔比
Investment Advisor
39.72%
Investment Advisor/Hedge Fund
37.82%
Hedge Fund
33.97%
Research Firm
2.86%
Venture Capital
1.35%
Individual Investor
0.84%
Bank and Trust
0.37%
Pension Fund
0.32%
Sovereign Wealth Fund
0.08%
機構持股
更新時間: 7月1日 週二
更新時間: 7月1日 週二
報告期間
機構數
持股數
持股佔比
持股變動
2025Q2
467
104.22M
117.36%
-10.96M
2025Q1
484
101.83M
114.67%
-16.19M
2024Q4
461
96.91M
109.26%
-9.67M
2024Q3
448
85.09M
109.18%
-32.25M
2024Q2
444
90.35M
118.12%
-28.07M
2024Q1
437
90.02M
118.29%
-22.39M
2023Q4
428
87.89M
116.97%
-15.26M
2023Q3
417
84.96M
113.19%
-18.05M
2023Q2
411
85.35M
113.93%
-14.35M
2023Q1
418
86.52M
116.25%
+3.17M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Armistice Capital LLC
8.87M
9.99%
+1.51M
+20.58%
Mar 31, 2025
Janus Henderson Investors
7.53M
8.48%
+3.47M
+85.50%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
6.72M
7.56%
+84.30K
+1.27%
Mar 31, 2025
The Vanguard Group, Inc.
5.00M
5.63%
-1.73M
-25.73%
Mar 31, 2025
Macquarie Investment Management
4.80M
5.4%
+537.76K
+12.62%
Mar 31, 2025
State Street Global Advisors (US)
3.65M
4.11%
-120.52K
-3.20%
Mar 31, 2025
Emerald Advisers LLC
3.20M
3.6%
-28.46K
-0.88%
Mar 31, 2025
Rock Springs Capital Management LP
2.92M
3.29%
-2.05M
-41.27%
Mar 31, 2025
Driehaus Capital Management, LLC
2.77M
3.12%
+549.72K
+24.78%
Mar 31, 2025
Renaissance Technologies LLC
2.70M
3.04%
+293.30K
+12.17%
Mar 31, 2025
查看更多
持股ETF
更新時間: 8月2日 週六
更新時間: 8月2日 週六
機構名稱
佔比
Invesco Pharmaceuticals ETF
2.61%
Virtus LifeSci Biotech Products ETF
1.91%
ALPS Medical Breakthroughs ETF
0.89%
SPDR S&P Biotech ETF
0.46%
First Trust Small Cap Growth AlphaDEX Fund
0.36%
Franklin Genomic Advancements ETF
0.35%
Direxion Daily S&P Biotech Bull 3X Shares
0.26%
Federated Hermes MDT Small Cap Core ETF
0.22%
First Trust Small Cap Core Alphadex Fund
0.2%
Vanguard US Momentum Factor ETF
0.17%
查看更多
Invesco Pharmaceuticals ETF
佔比2.61%
Virtus LifeSci Biotech Products ETF
佔比1.91%
ALPS Medical Breakthroughs ETF
佔比0.89%
SPDR S&P Biotech ETF
佔比0.46%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.36%
Franklin Genomic Advancements ETF
佔比0.35%
Direxion Daily S&P Biotech Bull 3X Shares
佔比0.26%
Federated Hermes MDT Small Cap Core ETF
佔比0.22%
First Trust Small Cap Core Alphadex Fund
佔比0.2%
Vanguard US Momentum Factor ETF
佔比0.17%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
